Karugu Caroline H, Binyaruka Peter, Ilboudo Patrick G, Sanya Richard E, Mohamed Shukri F, Kisia Lyagamula, Kibe Peter, Mashiashi Irene, Bunn Christopher, Mair F, Agyemang Charles, Mtenga Sally M, Asiki Gershim, Gray Cindy M, Grieve Eleanor, Deidda Manuela
Chronic Diseases Management, African Population and Health Research Center, Nairobi, Kenya.
Public and Occupation Health, Amsterdam Medical Center, University of Amsterdam, Amsterdam, Noord-Holland, The Netherlands.
BMJ Public Health. 2024 Aug 24;2(2):e000383. doi: 10.1136/bmjph-2023-000383. eCollection 2024 Dec.
COVID-19 affected healthcare access, utilisation and affordability, especially for patients suffering from chronic diseases, including type 2 diabetes (T2D). This study measured the occurrence and magnitude of changes in healthcare and broader societal costs among patients with T2D before and during COVID-19 in Kenya and Tanzania to understand whether and how COVID-19 affected T2D management in countries implementing different policies during the pandemic.
A cross-sectional study was conducted in Kenya and Tanzania in March-April 2022 among 500 patients with T2D in each country. We interviewed patients on direct healthcare costs (eg, inpatient and outpatient costs), societal costs (eg, productivity loss) and patients' characteristics before and during the COVID-19 pandemic. We estimated changes over time using the Generalised Linear Model in Kenya and a two-part model in Tanzania, adjusting for patient-level covariates.
The overall costs of management of T2D in most categories increased in both countries during COVID-19, but some of the increase was not significant. Transport and testing costs increased significantly in Tanzania (I$0.33, p<0.01 and I$0.85, p<0.01) but not in Kenya (I$1.69, p=0.659 and I$0.10, p=0.603). Outpatient costs increased significantly in Tanzania (I$8.84, p<0.01) but there was no significant change in Kenya (I$8.09, p=0.432). T2D medication costs did not change in Tanzania (I$0.19, p=0.197), but decreased significantly in Kenya (I$18.48, p<0.01). Productivity losses increased significantly in both countries.
The COVID-19 pandemic is associated with increased direct costs but with a significant increase in many cost categories (transport, testing and outpatient) in Tanzania than in Kenya. A significant increase in productivity loss was observed in both countries. The minimal cost increases in Kenya may be due to the inaccessibility of services associated with lockdown measures and higher insurance coverage compared with Tanzania. Pandemic preparedness initiatives and interventions are needed to safeguard the welfare of patients with chronic conditions during pandemics.
新冠疫情影响了医疗服务的可及性、利用率和可负担性,尤其是对患有包括2型糖尿病(T2D)在内的慢性病患者。本研究衡量了肯尼亚和坦桑尼亚T2D患者在新冠疫情之前和期间医疗保健及更广泛社会成本变化的发生率和幅度,以了解在疫情期间实施不同政策的国家中,新冠疫情是否以及如何影响T2D的管理。
2022年3月至4月在肯尼亚和坦桑尼亚进行了一项横断面研究,每个国家有500名T2D患者参与。我们就新冠疫情之前和期间的直接医疗成本(如住院和门诊费用)、社会成本(如生产力损失)以及患者特征对患者进行了访谈。我们在肯尼亚使用广义线性模型,在坦桑尼亚使用两部分模型估计随时间的变化,并对患者层面的协变量进行了调整。
在新冠疫情期间,两国大多数类别的T2D管理总成本都有所增加,但部分增加并不显著。坦桑尼亚的交通和检测成本显著增加(分别为0.33美元,p<0.01和0.85美元,p<0.01),而肯尼亚则不然(分别为1.69美元,p=0.659和0.10美元,p=0.603)。坦桑尼亚的门诊费用显著增加(8.84美元,p<0.01),而肯尼亚没有显著变化(8.09美元,p=0.432)。坦桑尼亚的T2D药物成本没有变化(0.19美元,p=0.197),但肯尼亚显著下降(18.48美元,p<0.01)。两国的生产力损失均显著增加。
新冠疫情与直接成本增加相关,但坦桑尼亚许多成本类别(交通、检测和门诊)的增加幅度比肯尼亚大。两国均观察到生产力损失显著增加。肯尼亚成本增加幅度最小可能是由于与封锁措施相关的服务不可及性以及与坦桑尼亚相比更高的保险覆盖率。需要采取大流行防范举措和干预措施,以在大流行期间保障慢性病患者的福利。